{"id":"W4321487567","doi":"10.1186/s12885-023-10642-7","title":"INTEGRATE II: randomised phase III controlled trials of regorafenib containing regimens versus standard of care in refractory Advanced Gastro-Oesophageal Cancer (AGOC): a study by the Australasian Gastro-Intestinal Trials Group (AGITG)","year":2023,"lang":"en","type":"article","venue":"BMC Cancer","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University Health Centre","funders":"National Health and Medical Research Council; Bayer HealthCare; Bristol-Myers Squibb","keywords":"Regorafenib; Medicine; Internal medicine; Oncology; Adverse effect; Placebo; Nivolumab; Clinical endpoint; Bevacizumab; Ramucirumab; Progression-free survival; Clinical trial; Cancer; Chemotherapy; Colorectal cancer; Immunotherapy; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00803922,0.0005769319,0.005768681,0.0005479314,0.0001513707,0.00003713331,0.0003644411,0.0001175771,0.0006987792],"category_scores_gemma":[0.004905448,0.0003734381,0.001039894,0.00104659,0.0002357827,0.0001645378,0.0001296313,0.0005120515,0.00000140093],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008379352,"about_ca_system_score_gemma":0.0009412983,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002204638,"about_ca_topic_score_gemma":0.007413826,"domain_scores_codex":[0.992552,0.001585497,0.003400585,0.0006800858,0.001037973,0.0007438388],"domain_scores_gemma":[0.9924806,0.003500292,0.002715825,0.0006457044,0.0004598873,0.0001976804],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9298902,0.0005411671,0.03196177,0.0003720177,0.001822466,0.0000896525,0.004672936,0.000714955,0.005687181,0.00004489788,0.005480494,0.01872233],"study_design_scores_gemma":[0.9146613,0.01682645,0.005913766,0.001323722,0.003675481,0.000002637811,0.05089801,0.0002996725,0.002141885,0.000007607615,0.003884232,0.0003652286],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9820217,0.004428608,0.0002225873,0.0005972411,0.001320158,0.01015531,0.0007356477,0.0001122999,0.000406472],"genre_scores_gemma":[0.9940297,0.0005936644,0.0002246997,0.00005535666,0.000406,0.002033547,0.0001309643,0.00006579101,0.00246028],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.04622507,"threshold_uncertainty_score":0.9998717,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06799051532900977,"score_gpt":0.4015266076578469,"score_spread":0.3335360923288372,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}